Richard C. Williams – Founder and President of Connor-Thoele Limited, Chairman
Mr. Williams has served as the founder and President of Conner-Thoele Limited, a consulting and financial advisory firm specializing in the healthcare industry and pharmaceutical segment. He has completed in excess of fifty divestments, acquisitions, financings and cross-border transactions, which have exceeded $8.0 billion. Prior to founding Conner-Thoele Limited in 1989, Mr. Williams served in a number of progressively responsible operational and financial management positions with multinational firms. These firms included American Hospital Supply Corporation, UNC Resources, Abbott Laboratories, Field Enterprises and Erbamont NV. Mr. Williams once served as a director and Vice Chairman of Strategic Planning for King Pharmaceuticals. Prior to King, he served as Chairman and a director of Medco Research before Medco was acquired by King Pharmaceuticals. Mr. Williams has also been on several other public and private Board of Directors, several as Chairman and a Director. These include Ista Pharmaceuticals, Vysis Pharmaceuticals, Immunemedics, EP Medical and Cellegy Pharmaceuticals. He was a member of the Listed Company Advisory Committee of New York Stock Exchange. Mr. Williams received a Bachelor of Arts degree in Economics from DePauw University and a Masters of Business Administration from the Wharton School of Finance.
Howard C. Birndorf
Mr. Birndorf is a biotechnology entrepreneur and one of the founders of the biotech industry in San Diego, California. In 1978, Birndorf co-founded San Diego’s first biotech, the monoclonal antibody company Hybritech. The company was subsequently bought by Eli Lilly and Company in 1986, and Mr. Birndorf went on to found or co-found a number of other successful companies including Gen-Probe, IDEC Pharmaceuticals (which merged with Biogen to form Biogen-Idec), and Ligand Pharmaceuticals. Birndorf was also involved in the formation of Gensia (Sicor) and was a director of Neurocrine Biosciences. He was the founder and co-chair of the Coalition for 21st Century Medicine and was co-founder, Chairman and CEO of Nanogen, Inc. Birndorf received his B.A. in Biology from Oakland University, an M.S. in Biochemistry from Wayne State University, and has received honorary Doctor of Science degrees from Oakland University and Wayne State University.
Ms. Blunt has more than 20 years of experience in the biopharmaceutical and medical device industries. Currently, Ms. Blunt founded and is managing director of 1798 Consultants, which is a national healthcare consulting firm focused on educating and developing strategies for clients to address healthcare compliance, reimbursement, health policy and patient access issues. She began her pharmaceutical career at The Boston Consulting Group, working primarily on cases in the healthcare industry. She has held a variety of strategic reimbursement and commercialization positions of increasing importance at Amgen, Inc. including involvement in the marketing of Aranesp and acting as global government affairs director in the company’s Washington DC office. Ms. Blunt was also the first global director of health economics and reimbursement for Biosense Webster, a Johnson & Johnson company. Prior to starting 1798 Consultants, she was vice president of strategy, planning, and communication at Long Beach Memorial Center and Miller Children’s Hospital. Ms. Blunt graduated from Princeton University, where she received her A.B. from the Woodrow Wilson School of International and Public Policy. She earned her M.B.A. from Kellogg School of Management at Northwestern University.
Dennis J. Carlo, Ph.D. – President, Chief Executive Officer
Dr. Carlo is a co-founder of Adamis Pharmaceuticals Corporation and has served as its President and Chief Executive officer since October 2006. Dr. Carlo has extensive biotechnology research and development experience. At Hybritech Inc., the first biotechnology company in San Diego, he served as Vice President of Research and Development and Therapeutic Manufacturing. There, he managed a successful program to carry out research and development in the areas of monoclonal antibody and cancer therapy. After Hybritech was acquired by Eli Lilly & Co in 1985, Dr. Carlo, along with Dr. Jonas Salk, James Glavin and Kevin Kimberlin, founded The Immune Response Corporation, a public company, where he served in various capacities including Chief Scientific Officer, COO and President and Chief Executive Officer. At The Immune Response Corporation, he established programs in Autoimmunity, Gene Therapy and HIV and led the product development in successful clinical trials. In 1991, while at Immune Response, Dr. Carlo was awarded “Entrepreneur of the Year” by Ernst & Young LLP. From 2003 to 2006, He served as president of Telos Pharmaceuticals, a private biotechnology company. Early in his career, as Director of Developmental and Basic Cellular Immunology and Director of Bacterial Vaccines and Immunology at Merck & Co., he oversaw research and product development for PNEUMOVAX (multi-valent polysaccharide vaccine), MENINGOVAX A, MENINGOVAX C, MENINGOVAX A-C, and H. influenzae type b, and also directed a multi-disciplinary task force whose goal was the development of novel adjuvants. Dr. Carlo received a B.S. degree in Microbiology from Ohio State University and has a Ph.D. in Immunology and Medical Microbiology from Ohio State University. He is named on 23 patents and has authored over 225 articles and abstracts in the field of Immunology.
David J. Marguglio - Senior Vice President, Chief Business Officer
Mr. Marguglio is a co-founder of Adamis and currently serves as Senior Vice President, Chief Business Officer and serves on the Board of Directors. He joined Adamis in 2006 as Vice President, Business Development and Investor Relations and from 2011 to 2017 served as Senior Vice President, Corporate Development. From 1996 to 2006, Mr. Marguglio held various positions with Citigroup Global Markets, Smith Barney and Merrill Lynch. Before entering the financial industry, from 1994 to 1996, he founded and ran two different startup companies, the latter of which was eventually acquired by a Fortune 100 company. Mr. Marguglio began his career as a financial analyst after receiving a degree in finance and management from the Hankamer School of Business at Baylor University.